Monday, November 12, 2012

AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

AASLD 2012: Danoprevir and Mericitabine Work for Prior Non-responders, Hep C Patients with Cirrhosis

Category: Experimental HCV Drugs
Published on Monday, 12 November 2012 00:00
Written by Liz Highleyman

 
Jordan Feld from Toronto Western Hospital Liver Centre and colleagues evaluated the safety and efficacy of different combination regimens containing the second-generation HCV protease inhibitor danoprevir, the nucleoside HCV polymerase inhibitor mericitabine, ribavirin, and for some participants, pegylated interferon alfa-2a (Pegasys).

Danoprevir is boosted with a small amount of ritonavir (Norvir) to reach higher levels in the body.
 
 View the results at HIV and Hepatitis

All AASLD Coverage @ HIV and Hepatitis

Highlights
Liver Meeting Highlights: New Hep C Drugs, NAFLD, Liver Cancer, Acetaminophen Toxicity, Benefits of Coffee

No comments:

Post a Comment